LegalView Reports Record Numbers of Drug Reactions in U.S., Partially Caused by Heparin

(PRLEAP.COM) Denver, CO — LegalView.com recently announced record high numbers of serious drug reactions and fatalities among Americans, according to data gathered by the watchdog group the Institute for Safe Medication Practices (ISMP). The record high was in part due to a blood thinner known as Baxter Heparin, which was found to be tainted. Patients who may have been subject to the Heparin side effects should consider consulting a pharmaceutical law firm, which will likely be able to provide insightful details as to the development of any potential Heparin lawsuit.

At the end of 2007, nearly 350 reports of serious side effects from patients began to surface. It was soon discovered that a batch of tainted Heparin had made its way into hospitals across the country from China. It is imperative that patients who may have received Heparin during a medical procedure contact an experienced pharmaceutical attorney to explore the potential for a Heparin class action lawsuit, which may offer monetary compensation for the damages caused by the tainted blood thinner.

In addition to reporting information on the tainted Heparin, LegalView also offers information on a range of other topics, all of which have recently been re-launched to offer victims of legal issues the most up-to-date news and information. For example, LegalView offers information portals on topics such as the rare, but serious mesothelioma cancer as well as information on traumatic brain injuries. LegalView also offers coverage on several other pharmaceutical drugs including Avandia.

Mesothelioma is a serious and rare cancer that is becoming more common among the U.S. elderly population. Mesothelioma cancer is caused by the exposure of an individual to asbestos fibers and dust. It takes years and, in most cases, decades before symptoms of mesothelioma become apparent. Even then the mesothelioma symptoms are often misdiagnosed for other similar conditions, which negatively effects an individual’s treatment success.

Another of LegalView’s most recently re-launched information portals is that of the traumatic brain injury (TBI) site. More than 5 million Americans currently suffer from TBI, and thousands, if not millions, of those victims go undiagnosed, leading to a potentially severe or fatal outcome. The number of TBI victims is also growing as thousands of U.S. soldiers returning from the war in Iraq are plagued by traumatic brain injury.

For information on other controversial pharmaceuticals, individuals can use the LegalView library to find the latest on unsafe drugs, such as the type 2 diabetes drug Avandia. However, within the last couple of years, Avandia has been linked to heart failure and heart damage as well as bone fractures/breaks and early on-set osteoporosis. Those who have consumed Avandia and may suffer from one of these risks should consult a medical professional immediately. Additionally, contacting an experienced Avandia attorney may also provide assistance to an injured person.

About LegalView:

LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation’s most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com’s superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com/
Contact Information
Katie Kelley
LegalView.com
720-226-6613
Email LegalView.com

About This News Release

If you have any questions regarding information in these press releases please contact the organization listed in the press release. Issuers of press releases and not PR Leap are solely responsible for the accuracy of the content.

Share this News
PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy